Claims
- 1. A pharmaceutical composition comprising (i) Factor VIIa or a Factor VIIa variant and (ii) Factor XIII or a Factor XIII variant.
- 2. The composition according to claim 1, comprising a Factor VII variant.
- 3. The composition according to claim 1, wherein the Factor VIIa is human Factor VIIa
- 4. The composition according to claim 1, wherein the Factor VIIa is recombinant human Factor VIIa and the Factor XIII is recombinant human Factor XIII.
- 5. A composition according to claim 1, wherein the Factor XIII is the a2-dimer of Factor XIII.
- 6. A composition according to claim 1, wherein the Factor XIII is activated Factor XIII.
- 7. A composition according to claim 1, wherein the composition further comprises a TFPI inhibitor.
- 8. A composition according to claim 1, wherein the composition further comprises Factor VIII.
- 9. A kit containing a treatment for bleeding episodes, said kit comprising
a) an effective amount of Factor VIIa or a Factor VIIa variant and a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of Factor XIII or a Factor XIII variant and a pharmaceutically acceptable carrier in a second unit dosage form; and c) a container means for containing said first and second dosage forms.
- 10. A kit according to claim 9 further comprising an effective amount of a TFPI inhibitor and a pharmaceutically acceptable carrier in a third unit dosage form.
- 11. A kit containing a treatment for bleeding episodes, said kit comprising
a) an effective amount of (i) Factor VIIa or a Factor VIIa variant and (ii) a TFPI inhibitor and a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of Factor XIII or a Factor XIII variant and a pharmaceutically acceptable carrier in a second unit dosage form; and c) a container means for containing said first and second dosage forms.
- 12. A kit containing a treatment for bleeding episodes, said kit comprising
a) an effective amount of Factor VIIa or a Factor VIIa variant and a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of (i) Factor XIII or a Factor XIII variant and (ii) a TFPI inhibitor and a pharmaceutically acceptable carrier in a second unit dosage form; and c) a container means for containing said first and second dosage forms.
- 13. A kit according to claim 9, further comprising Factor VIII or a Factor VIII variant, wherein said Factor VIII or Factor VIII variant is either formulated in a unit dosage form separate from (a) or (b) or is contained within (a) or (b).
- 14. A kit according to claim 10, further comprising Factor VIII or a Factor VIII variant, wherein said Factor VIII or Factor VIII variant is either formulated in a unit dosage form separate from (a) or (b) or is contained within (a) or (b).
- 15. A kit according to claim 11, further comprising Factor VIII or a Factor VIII variant, wherein said Factor VIII or Factor VIII variant is either formulated in a unit dosage form separate from (a) or (b) or is contained within (a) or (b).
- 16. A method for treating bleeding episodes in a subject in need of such treatment, said method comprising administering to said subject (i) a first amount of Factor VIIa or a Factor VIIa variant and (ii) a second amount of Factor XIII or a Factor XIII variant, wherein said first and second amounts together are effective to treat said bleeding episode.
- 17. A method according to claim 16, wherein said treatment comprises reducing clotting time in said subject.
- 18. A method according to claim 16, wherein said treatment comprises prolonging clot lysis time in said subject.
- 19. A method according to claim 16, wherein said treatment comprises increasing clot strength in said subject.
- 20. A method according to claim 16, wherein said treatment comprises enhancing fibrin clot formation in said subject.
- 21. A method claim according to claim 16, wherein the Factor VIIa or Factor VIIa variant and the Factor XIII or Factor XIII variant are administered in a single dosage form.
- 22. A method claim according to claim 16, wherein the Factor VIIa or Factor VIIa variant and the Factor XIII or Factor XIII variant are administered sequentially.
- 23. A method according to claim 16, further comprising administering a third amount of a TPFI inhibitor, wherein said first, second, and third amounts together are effective for said treatment.
- 24. A method according to claim 16, further comprising administering a third amount of Factor VIII or a Factor VIII variant, wherein said first, second, and third amounts together are effective for said treatment
Priority Claims (3)
Number |
Date |
Country |
Kind |
PA 2000 00778 |
May 2000 |
DK |
|
PA 2000 00771 |
May 2000 |
DK |
|
PA 2000 00871 |
Jun 2000 |
DK |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of PCT/DK01/00322 filed on May 10, 2001, and claims priority under 35 U.S.C. 119 of Danish application no. PA 2000 00778 filed on May 10, 2000, Danish application no. PA 2000 00771 filed on May 10, 2000, Danish application no. PA 2000 00871 filed on Jun. 6, 2000, U.S. provisional application No. 60/206,194 filed on May 22, 2000, U.S. provisional application No. 60/206,212 filed on May 22, 2000, and U.S. provisional application No. 60/212,857 filed on Jun. 20, 2000, the contents of which are fully incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/DK01/00322 |
May 2001 |
US |
Child |
10271278 |
Oct 2002 |
US |